NR3C2
Mineralocorticoid receptor
As of the edition of 20 October 2026, NR3C2 (mineralocorticoid receptor, UniProt P08235) has 21 drugs tested at it and 26 companies on the list, 5 on route A and 11 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P08235
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 30
- Disease areas
- Heart and blood vessels; Urinary and reproductive; Pregnancy and women's health; Hormones; Nutrition and metabolism; Nervous system; Cancer; Inherited and neonatal
- Registered trials of its drugs
- 530
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 13 |
| Active | 2 |
| Went quiet | 3 |
| Stopped | 3 |
| Total | 21 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Spironolactone | Marketed | Phase 4 | none listed |
| Finerenone | Marketed | Phase 4 | Ends 2035 |
| Eplerenone | Marketed | Phase 4 | none listed |
| Drospirenone | Marketed | Phase 4 | none listed |
| Fludrocortisone | Marketed | Phase 4 | none listed |
| Nimodipine | Marketed | Phase 4 | none listed |
| Balcinrenone | Active | Phase 3 | none listed |
| Fludrocortisone acetate | Marketed | Phase 4 | none listed |
| Vamorolone | Marketed | Phase 4 | Ends 2040 |
| Felodipine | Marketed | Phase 4 | none listed |
| XL550 | Went quiet | Phase 3 | none listed |
| MT-3995 | Went quiet | Phase 2 | none listed |
12 of 21 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 5 |
| Route B | 11 |
| Engaged | 4 |
| Undetermined | 6 |
| Total on the list | 26 |
| Company | Route |
|---|---|
| AstraZeneca | Route B |
| Pfizer | Route B |
| KBP Biosciences | Route A |
The other 23 companies at NR3C2
In the product26 companies in all; 23 are not named here, and no score is.
See the 26 companies at NR3C2, ranked, with the facts behind eachRequest access. Nothing is shown until you do.